Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 3 5 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN 3.5% vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution